title: Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.
authors.affiliation: University Hospital Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Platzbecker
authors.affiliation: Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Sekeres
authors.affiliation: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: H
authors.initials: H
authors.lastname: Kantarjian
authors.affiliation: Clinic for Oncology, Hematology and Palliative Medicine, Marien Hospital Düsseldorf, Düsseldorf, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Giagounidis
authors.affiliation: King's College London, London, UK.
authors.forename: G J
authors.initials: GJ
authors.lastname: Mufti
authors.affiliation: Amgen Inc., South San Francisco, CA, USA.
authors.forename: C
authors.initials: C
authors.lastname: Jia
authors.affiliation: Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Yang
authors.affiliation: Service d'hématologie clinique, Hopital Avicenne Universite Paris XIII, Bobigny, France.
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
mesh_terms: D006801:Humans; D009190:Myelodysplastic Syndromes / Q000097:blood* / Q000150:complications* / Q000401:mortality; D010976:Platelet Count; D011961:Receptors, Fc / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality; D013926:Thrombopoietin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim